MapLight Therapeutics, Inc.
MPLT Nasdaq
SEC CIK 1770069
Follow MapLight Therapeutics
Weekly email: filings, results
Net income
−$51.6M
−75.5% vs same quarter last year
EPS, diluted
−$0.97
+97.4% vs same quarter last year
Operating cash flow
−$35.7M
−12.2% vs same quarter last year
Operating income
−$55.3M
−75.7% vs same quarter last year
Source: SEC XBRL filings · latest filing